Rinri Therapeutics is a pioneering biotechnology spin-out from the University of Sheffield, dedicated to reversing sensorineural hearing loss using regenerative cell therapy. Founded on over two decades of Professor Marcelo Rivolta’s stem-cell research, the company employs its proprietary OSPREY™ platform to produce otic neural progenitor cells that mature into functional auditory neurons, aiming to reconnect damaged inner-ear circuits. Their lead candidate, Rincell‑1, has delivered impressive preclinical results—restoring hearing in animal models by regenerating neurons and improving thresholds by around 40%—and is now advancing into a UK Phase I/IIa human trial in conjunction with cochlear implantation. Backed by major investors and a £20 million Series A round, Rinri is gearing up to bring a first-ever disease‑modifying treatment for neural hearing loss to patients worldwide.